A Study of LY3841136 in Japanese Participants With Obesity or Overweight

NCT06297616 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the drug LY3841136 in Japanese adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 128 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-04 · est. completion 2025-11

Where 3 sites · Japan

What this study is testing ClinicalTrials.gov NCT06297616 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.

Treatments tested

LY3841136 Drug

Administered SC
LY3841136-Placebo Drug

Administered SC
Tirzepatide Drug

Administered SC
Tirzepatide-Placebo Drug

Administered SC

Main thing measured	Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06297616 ↗